Triple-negative Breast Cancer

• CLINICAL_TRIALS trial_result · 2022-07-18
  Clinical Trial Update: Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency [Phase 2]

  Phase II trial update for niraparib in metastatic triple negative breast cancer with homologous recombination deficiency.

• CLINICAL_TRIALS trial_result · 2022-07-12
  Clinical Trial Update: AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer [Phase 2]

  Phase 2 trial update evaluating AK105 plus anlotinib hydrochloride with albumin paclitaxel as first-line therapy for advanced triple-negativ…

• CLINICAL_TRIALS trial_result · 2022-07-05
  Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) [Phase 3]

  This Phase 3 study evaluated pembrolizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy for locally recurrent in…

• CLINICAL_TRIALS trial_result · 2022-06-30
  Clinical Trial Update: A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer [Phase 2]

  Phase 2 clinical trial evaluating chidamide in combination with camrelizumab and either carboplatin or capecitabine for second/third line re…

• CLINICAL_TRIALS trial_result · 2022-06-10
  Clinical Trial Update: Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer [Phase 2]

  Phase 2 trial evaluating pembrolizumab plus enobosarm in androgen receptor-positive metastatic triple-negative breast cancer has completed w…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-06-02
  Clinical Trial Update: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer [Phase 2]

  Phase 2 trial evaluating eribulin in combination with an anti-PD-1 antibody in metastatic triple-negative breast cancer (TNBC).

• CLINICAL_TRIALS trial_result · 2022-05-13
  Clinical Trial Update: A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer [Phase 2]

  Phase 2 trial evaluating efficacy and safety of LAG525 with spartalizumab, with or without carboplatin, in advanced triple-negative breast c…

• CLINICAL_TRIALS trial_result · 2022-05-03
  Clinical Trial Update: Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery [Phase 2]

  Phase 2 trial of entinostat with anastrozole in postmenopausal women with resectable triple-negative breast cancer (TNBC) was terminated; re…

• CLINICAL_TRIALS trial_result · 2022-04-25
  Clinical Trial Update: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer [Phase 1]

  Phase 1 trial investigating eribulin mesylate and everolimus in triple-negative metastatic breast cancer has completed with results posted.

• CLINICAL_TRIALS trial_result · 2022-04-22
  Clinical Trial Update: ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) [Phase 3]

  Phase 3 trial comparing ABX plus cisplatin to gemcitabine plus cisplatin in triple-negative breast cancer has completed.

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer [Phase 2]

  Phase 2 trial comparing vinorelbine plus apatinib to vinorelbine alone in advanced triple-negative breast cancer has completed.

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Platinum Rechallenge in Patients With Platinum-sensitive mTNBC [Phase 2]

  Phase 2 clinical trial evaluating platinum rechallenge in patients with platinum-sensitive metastatic triple-negative breast cancer.

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer [Phase 2]

  Phase 2 study evaluating PVX-410 in combination with pembrolizumab and chemotherapy for metastatic PD-L1 positive triple-negative breast can…

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer [Phase 2]

  Phase 2 clinical trial evaluating guided treatment using mini-PDX in metastatic triple-negative breast cancer.

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer [Phase 2]

  Phase 2 clinical trial update investigating chidamide in combination with cisplatin for relapsed or metastatic triple-negative breast cancer…

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: ImmunoBreast - A Phase Ib Study [Phase 1, Phase 2]

  Phase I/II clinical trial update for ImmunoBreast in breast cancer, including triple-negative and metastatic disease, with unspecified statu…

• CLINICAL_TRIALS trial_result · 2022-04-20
  Clinical Trial Update: Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) [Phase 2]

  Phase 2 trial comparing gemcitabine plus cisplatin vs gemcitabine plus carboplatin in triple-negative breast cancer.

• CLINICAL_TRIALS trial_result · 2022-03-23
  Clinical Trial Update: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) [Phase 2]

  Phase 2 trial of trilaciclib in combination with gemcitabine and carboplatin in metastatic triple-negative breast cancer was terminated; res…

• CLINICAL_TRIALS trial_result · 2022-03-22
  Clinical Trial Update: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. [Phase 2]

  Phase 2 trial evaluating DNA damage repair–targeting strategies with Olaparib versus Olaparib monotherapy in metastatic triple-negative brea…

• CLINICAL_TRIALS trial_result · 2022-03-22
  Clinical Trial Update: Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients [Phase 2]

  Phase 2 clinical trial update evaluating nivolumab after induction treatment in triple-negative breast cancer patients.

• CLINICAL_TRIALS trial_result · 2022-03-21
  Clinical Trial Update: Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature [Phase 2]

  A Phase 2 clinical trial evaluating the efficacy of talazoparib in Asian patients with metastatic breast cancer characterized by homologous …

• CLINICAL_TRIALS trial_result · 2022-03-10
  Clinical Trial Update: ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

  Phase 2 trial of ONC201 with a methionine-restricted diet in metastatic triple negative breast cancer was terminated; results posted in 2022…

• CLINICAL_TRIALS trial_result · 2022-02-25
  Clinical Trial Update: Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR [Phase 2]

  Phase 2 window-of-opportunity trial evaluating dasatinib in operable triple-negative breast cancer; trial status terminated with results pos…

• CLINICAL_TRIALS trial_result · 2022-02-24
  Clinical Trial Update: A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients [Phase 2]

  Phase 2 trial evaluating ctDNA blood tests to detect residual cancer after standard treatment and trigger additional therapy in early-stage …

• CLINICAL_TRIALS trial_result · 2022-02-18
  Clinical Trial Update: MicroRNA Profiles in Triple Negative Breast Cancer [Phase 2]

  Phase 2 clinical trial exploring microRNA profiles in triple negative breast cancer.